Evidence map›Paper›PMID 38267023›Full record

Trial reportNeuropsychopharmacology reports2024

Feasibility of remote interviews in assessing disease severity in patients with major depressive disorder: A pilot study.

Tomiki Sumiyoshi, Yasunori Morio, Takahiro Kawashima, Hisateru Tachimori, Seiji Hongo, Taishiro Kishimoto, Koichiro Watanabe, Tempei Otsubo, Hideki Oi, Kazuyuki Nakagome and 1 more

Open access · goldAbstract readRandomized Controlled TrialMulticenter Study
In one paragraph

Trial report in Neuropsychopharmacology reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.3field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Trial
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 6 institutions in 2 countries.

Tomiki SumiyoshiNational Center of Neurology and Psychiatry, Tokyo, Japan.ORCID https://orcid.org/0000-0001-9629-1671
Yasunori MorioNational Center of Neurology and Psychiatry, Tokyo, Japan.
Takahiro KawashimaNational Center of Neurology and Psychiatry, Tokyo, Japan.
Hisateru TachimoriNational Center of Neurology and Psychiatry, Tokyo, Japan.
Seiji HongoIchigaya Himorogi Clinic, Tokyo, Japan.
Taishiro KishimotoHills Joint Research Laboratory for Future Preventive Medicine and Wellness, Keio University School of Medicine, Tokyo, Japan.ORCID https://orcid.org/0000-0003-0557-8648
Koichiro WatanabeDepartment of Neuropsychiatry, Kyorin University School of Medicine, Tokyo, Japan.
Tempei OtsuboDepartment of Psychosomatic & Psychiatric Medicine, Tokyo Women's Medical University Adachi Medical Center, Tokyo, Japan.
Hideki OiNational Center of Neurology and Psychiatry, Tokyo, Japan.
Kazuyuki NakagomeNational Center of Neurology and Psychiatry, Tokyo, Japan.ORCID https://orcid.org/0000-0003-2919-8180
Jun IshigookaIshigooka Hospital, Chiba, Japan.
National Center of Neurology and Psychiatry · JPAims Community College · USKeio University · JPKyorin University · JPTaoka Hospital · JPTokyo Women's Medical University Adachi Medical Center · JP

Funding

Janssen Pharmaceutical K.K.Meiji Seika Pharma Co., Ltd.Otsuka Pharmaceutical Co., Ltd.Shionogi & Co., Ltd.Sumitomo Pharma Co., Ltd.Takeda Pharmaceutical Company Limited
6 · The paper itself

Abstract

aimInterview quality is an important factor in the success of clinical trials for major depressive disorder (MDD). There is a substantial need to establish a reliable, remote clinical assessment interview system that can replace traditional in-person interviews.

methodsWe conducted a multicenter, randomized, unblinded, prospective, cross-sectional study to assess the reliability of remote interviews in patients with MDD (UMIN000041839). Eligible patients with MDD underwent remote and in-person sessions of the Montgomery-Åsberg Depression Rating Scale (MADRS) assessment performed by different raters within 28 days of providing consent. Patients were randomized to a group first assessed using in-person interviews and secondarily using remote interviews (in-person-first group) or a group first assessed by remote interviews and secondarily using in-person interviews (remote-first group). Nineteen trained people (15 clinical psychologists, 3 nurses, and 1 clinical laboratory technologist) performed interviews.

resultsOf 59 patients (in-person-first group, n = 32; remote-first group, n = 27) who completed both remote and in-person interviews, 51% (n = 30) were women; the mean age was 41.6 years (range, 21-64 years). There was a strong association between remote and in-person MADRS scores (r = 0.891, kappa = 0.901). An overall intraclass correlation coefficient (ICC) of 0.886 (95% confidence interval, 0.877-0.952) indicated good consistency between MADRS scores in remote and in-person interviews. The ICC decreased as the severity of depression increased.

conclusionOur results suggest remote interviews are a feasible alternative option to in-person interviews in assessing symptom severity in MDD patients and could promote clinical trials in Japan.

Indexed as

Major Depressive DisorderAdultCross-Sectional StudiesEast Asian PeopleFeasibility StudiesFemaleHumansMaleMiddle AgedPatient AcuityPilot ProjectsProspective StudiesReproducibility of ResultsYoung Adultmajor depressive disordermobile applicationspilot projectpsychiatric status rating scalepsychological interviews

Identifiers

PMID38267023
PMCPMC10932799
OpenAlexW4391187889

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.